Abstract
Objectives: A considerable number of patients do not achieve an adequate response to clopidogrel. Our study aimed to evaluate genetic and non-genetic factors as possible risks for clopidogrel high on-treatment platelet reactivity (HTPR) in patients (n=112) with carotid artery stenosis undergoing endarterectomy (CEA).
Methods: Using multiple-electrode impedance aggregometry (MEA) the antiplatelet effectiveness of clopidogrel was measured after 24 h, 7 and 30 days of clopidogrel treatment, which was introduced after elective CEA at a dose of 75 mg daily, for at least 30 days.
Results: HTPR was observed among 25% patients after clopidogrel therapy for 30 days. Further analysis showed that 53.3% of patients carrying the CYP2C19*2 gene variant had clopidogrel-HTPR, while in the wild type group there were 14.6% (p<0.001). Multivariate logistic regression analysis identified the CYP2C19*2 variant allele (OR 4.384; 95% CI 1.296-14.833, p=0.017) and high total cholesterol level (OR 2.090; 95% CI 1.263-3.459, p=0.004) as the only independent risk factors for clopidogrel-HTPR.
Conclusion: The CYP2C19*2 gene variant and high total cholesterol level were major factors for clopidogrel- HTPR in patients with carotid artery stenosis undergoing CEA.
Keywords: Carotid artery stenosis, carotid endarterectomy, clopidogrel, platelet reactivity, risk factors, CYP2C19*2.
Current Vascular Pharmacology
Title:Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study
Volume: 14 Issue: 6
Author(s): Dragana Backovic, Svetlana Ignjatovic, Ljiljana Rakicevic, Mirjana Novkovic, Jelena Kusic-Tisma, Dragica Radojkovic, Evgenija Strugarevic, Branko Calija, Djordje Radak and Mirjana Kovac
Affiliation:
Keywords: Carotid artery stenosis, carotid endarterectomy, clopidogrel, platelet reactivity, risk factors, CYP2C19*2.
Abstract: Objectives: A considerable number of patients do not achieve an adequate response to clopidogrel. Our study aimed to evaluate genetic and non-genetic factors as possible risks for clopidogrel high on-treatment platelet reactivity (HTPR) in patients (n=112) with carotid artery stenosis undergoing endarterectomy (CEA).
Methods: Using multiple-electrode impedance aggregometry (MEA) the antiplatelet effectiveness of clopidogrel was measured after 24 h, 7 and 30 days of clopidogrel treatment, which was introduced after elective CEA at a dose of 75 mg daily, for at least 30 days.
Results: HTPR was observed among 25% patients after clopidogrel therapy for 30 days. Further analysis showed that 53.3% of patients carrying the CYP2C19*2 gene variant had clopidogrel-HTPR, while in the wild type group there were 14.6% (p<0.001). Multivariate logistic regression analysis identified the CYP2C19*2 variant allele (OR 4.384; 95% CI 1.296-14.833, p=0.017) and high total cholesterol level (OR 2.090; 95% CI 1.263-3.459, p=0.004) as the only independent risk factors for clopidogrel-HTPR.
Conclusion: The CYP2C19*2 gene variant and high total cholesterol level were major factors for clopidogrel- HTPR in patients with carotid artery stenosis undergoing CEA.
Export Options
About this article
Cite this article as:
Backovic Dragana, Ignjatovic Svetlana, Rakicevic Ljiljana, Novkovic Mirjana, Kusic-Tisma Jelena, Radojkovic Dragica, Strugarevic Evgenija, Calija Branko, Radak Djordje and Kovac Mirjana, Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study, Current Vascular Pharmacology 2016; 14 (6) . https://dx.doi.org/10.2174/1570161114666160714103148
DOI https://dx.doi.org/10.2174/1570161114666160714103148 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epoxyeicosatrienoic Acids as a Therapeutic Target for Nephropathy Associated with Diabetes and Hypertension
Current Hypertension Reviews Psoriatic Arthritis and Risk of Vertebral Fracture: A Systematic Review and Meta-Analysis
Current Rheumatology Reviews The Role of the Novel Adipocyte-Derived Protein Adiponectin in Human Disease: An Update
Mini-Reviews in Medicinal Chemistry Further LDL Cholesterol Lowering Through Targeting PCSK9 for Coronary Artery Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery Diabetes and Vascular Disease: Is It All About Glycemia?
Current Pharmaceutical Design DNA-Damaging Anticancer Drugs – A Perspective for DNA Repair- Oriented Therapy
Current Medicinal Chemistry Are Cerebrovascular White Matter Lesions an Early Sign of Vascular Cognitive Impairment and Vascular Dementia?
Vascular Disease Prevention (Discontinued) Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Current Gene Therapy Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews Potential Role of Polyphenols in the Prevention of Cardiovascular Diseases: Molecular Bases
Current Medicinal Chemistry Bergamot Juice Extract Inhibits Proliferation by Inducing Apoptosis in Human Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Metformin Beyond Diabetes: New Life for an Old Drug
Current Diabetes Reviews The Role of PPARs in Obesity and other Insulin Resistance Associated Disorders
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Bioactivity and Pharmacological Actions of Carbon Monoxide-Releasing Molecules
Current Pharmaceutical Design Editorial [Exploring Neural-Immune System Interactions]
Current Immunology Reviews (Discontinued) IL-1 Cytokines in Cardiovascular Disease: Diagnostic, Prognostic and Therapeutic Implications
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacological and Non Pharmacological Strategies in the Management of Coronary Artery Disease and Chronic Kidney Disease
Current Cardiology Reviews Trans-Plasma Membrane Electron Transport in Human Blood Platelets
Mini-Reviews in Medicinal Chemistry Lymphocyte Homing to the Liver
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents